Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Condition: Mantle Cell Lymphoma (MCL) Intervention: Sponsors: Peking University Third Hospital; Peking Union Medical College Hospital; The Second Affiliated Hospital of Dalian Medical University; Peking University First Hospital; Beijing Tongren Hospital; Beijing Hospital; Beijing Tsinghua Changgeng Hospital; China-Japa n Friendship Hospital; 307 Hospital of PLA; Chinese PLA General Hospital; First Affiliated Hospital of Harbin Medical University; Harbin Medical University; Baotou Cancer Hospital; Beijing Shijitan Hospital, Capital Medical University; Shanxi Province Cancer Hospi tal; Beijing Naval General Hospital; First Hospital of China Medical University; Jilin Provincial Tumor Hospital; Shengjing Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials